QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
NASDAQ:IMNP

Immune Pharmaceuticals (IMNP) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free IMNP Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
12.29 million shs
Market Capitalization
$8.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
IMNP stock logo

About Immune Pharmaceuticals Stock (NASDAQ:IMNP)

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Englewood Cliffs, New Jersey.

IMNP Stock News Headlines

April 11, 2024 | msn.com
Vertex Pharmaceuticals Seeks a Second Act With Alpine Immune Deal. What Wall Street Says.
April 11, 2024 | msn.com
These Stocks Are Moving the Most Today: Alpine Immune, Regeneron, Costco, Constellation Brands, CarMax, and More
April 19, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
April 11, 2024 | msn.com
These Stocks Are Moving the Most Today: Alpine Immune, Vertex, Regeneron, Costco, Constellation Brands, CarMax, and More
April 2, 2024 | markets.businessinsider.com
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology
December 15, 2023 | tmcnet.com
AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial
December 15, 2023 | markets.businessinsider.com
AC Immune Advances Anti-pTau Active Immunotherapy For Alzheimer's Disease Into Phase 2b Trial
September 14, 2023 | benzinga.com
Immune Health Supplements Market US$ 63,457.4 Million Valuation in 2033, Experiencing an Impressive CAGR of 10.4% | Future Market Insights Inc.
April 19, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
June 8, 2023 | es-us.finanzas.yahoo.com
Organ Transplant Rejection Medication Market to Surpass USD 7.0 Billion by 2031, Propelled by Remarkable CAGR of 3.9% | Transparency Market Research
June 6, 2023 | finanznachrichten.de
Theralase Technologies Inc.: Theralase Announces Appointment of New Independent Director
June 6, 2023 | finance.yahoo.com
Theralase(R) Announces Appointment of New Independent Director
June 5, 2023 | msn.com
Several Down syndrome features may be linked to a hyperactive antiviral immune response – new research
June 2, 2023 | finanznachrichten.de
Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
June 2, 2023 | finance.yahoo.com
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
June 1, 2023 | finanznachrichten.de
Medexus Pharmaceuticals Inc.: Medexus to Participate in the LD Micro Invitational XIII
June 1, 2023 | finance.yahoo.com
Bristol Myers (BMY) Loses 10.5% Year-to-Date: What Lies Ahead?
June 1, 2023 | markets.businessinsider.com
Hookipa Pharma (HOOK) Gets a Buy from JMP Securities
May 30, 2023 | markets.businessinsider.com
Phanes Therapeutics announces the appointment of Rita Laeufle, MD, PhD, as Chief Medical Officer
May 29, 2023 | markets.businessinsider.com
X4 Pharmaceuticals (XFOR) Gets a Buy from Stifel Nicolaus
May 27, 2023 | nasdaq.com
HC Wainwright & Co. Reiterates Eledon Pharmaceuticals (ELDN) Buy Recommendation
May 23, 2023 | finance.yahoo.com
CalciMedica Expands Executive Team with New Appointments
May 17, 2023 | technews.tmcnet.com
Biotech Entrepreneur and Venture Capitalist Dinesh Patel Discusses Therapeutics and Medical Devices with CancerVAX CEO Ryan Davies
May 17, 2023 | marketwatch.com
Myocardial Infarction Drugs Market Size and Projection from 2023 to 2030
May 17, 2023 | markets.businessinsider.com
B.Riley Financial Sticks to Their Buy Rating for X4 Pharmaceuticals (XFOR)
May 16, 2023 | benzinga.com
CAR T-Cell Therapy Market to be Worth $51.6 Billion by 2030 - Exclusive Report by Meticulous Research®
May 12, 2023 | marketwatch.com
Liver Failure Therapeutics Market 2023-2031: Analyzing Growth Opportunities and Challenges
See More Headlines
Receive IMNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immune Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/15/2018
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMNP
Previous Symbol
OTCMKTS:EPCT
CUSIP
N/A
CIK
1208261
Web
www.immunepharmaceuticals.com
Phone
201-464-2677
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
49,313,000
Free Float
N/A
Market Cap
$8.14 million
Optionable
Not Optionable
Beta
N/A
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Elliot M. Maza CPA (Age 62)
    J.D., MBA, CPA, Pres, CEO, Principal Financial Officer, Principal Accounting Officer, Sec. & Director
  • Dr. Anthony S. Fiorino (Age 51)
    COO & Chief Medical Officer
  • Mr. Christine J. Petraglia
    Director of Investor Relations
  • Ms. Anna Baran-Djokovic J.D.
    Director of Corp. Affairs
  • Dr. Miri Ben-Ami
    Pres of Immune Oncology Pharmaceuticals Inc

Key Competitors

View All Competitors

IMNP Stock Analysis - Frequently Asked Questions

How were Immune Pharmaceuticals' earnings last quarter?

Immune Pharmaceuticals Inc (NASDAQ:IMNP) released its quarterly earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.05.

What other stocks do shareholders of Immune Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immune Pharmaceuticals investors own include Neovasc (NVCN), LadRx (CYTR), Biopharmx (BPMX), Synergy Pharmaceuticals (SGYP), Gevo (GEVO), Pernix Therapeutics (PTX), Sorrento Therapeutics (SRNE), Novavax (NVAX), DryShips (DRYS) and Heat Biologics (HTBX).

This page (NASDAQ:IMNP) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
SHOCKING Crypto Leak…
Crypto 101 Media
Man Who Predicted 2008: “This Will be Worse.”
Altimetry
Fed launches fourth dollar overhaul
Stansberry Research